This debate presents a genuine quality-vs-entry-timing tension where the bear wins the near-term tactical argument while the bull wins the structural thesis. The fundamentals are genuinely strong — Q2 2026 showed revenue of $24.71B (+14.5% YoY), operating income of $2.81B (+30.7% YoY), and EPS of $1.57 (+28.7% YoY) with margin expansion running 16 points faster than revenue. The $22.9B Tomahawk contract is real contracted backlog, net debt has come down $8B YoY to $29.1B, FCF TTM is $9.88B, and the structural defense spending thesis is intact. However, the technical picture is unambiguously late-stage: RSI at 71.7 after a 17% rally in 5 weeks, MACD histogram turning negative at -0.40, and a forward P/E of 28.7x is rich for a defense industrial that historically trades at 15-20x. The 1% reaction to a $22.9B contract signals market skepticism on margin profile and execution risk. This is a quality compounder at a poor entry point — maintain positions but do not add here; wait for pullback to $210-215 zone or 2-3 week sideways consolidation.

POSITION STRATEGY: Maintain existing RTX position. Do not sell. The structural thesis (defense super-cycle, Tomahawk backlog, 28.7% YoY EPS growth, deleveraging balance sheet) is intact and selling a quality compounder into a technical wobble is almost always a mistake.

POSITION STRATEGY: Do not add to the position at current levels ($225+). The risk/reward is asymmetric to the downside near-term: RSI at 71.7 suggests 5-10% pullback risk over the next 2-4 weeks; MACD histogram at -0.40 with potential to deepen before resetting; price at 78% of Bollinger Band range; 1% reaction to $22.9B catalyst signals market skepticism on margin profile; long-end yields at 19-year highs create multiple compression risk on a 28.7x forward P/E.

ENTRY TRIGGERS: Set buy-triggers for incremental adds at better levels: Primary trigger at $210-215 zone (10 EMA $221.27 / 20 SMA confluence, roughly 5-7% below current) — add on elevated volume with RSI mean-reverting toward 50; Secondary trigger at $200-203 zone (50 SMA area, prior breakout level) — only likely on broader market correction or RTX-specific news shock; Tertiary trigger: sideways consolidation 2-3 weeks at current levels with RSI cooling to 55-60 and MACD histogram resetting toward zero.

POSITION SIZING: Total RTX exposure should not exceed benchmark weight pending a better entry. If currently underweight, do not chase to neutral — accept the underweight and add on weakness. If currently at or above benchmark weight, hold steady.

RISK MANAGEMENT: If RTX closes below $217.55 (10 EMA) on volume, reassess — that would be the first technical break of the uptrend structure and would warrant a more cautious stance. If it closes below $200 (50 SMA area), the structural thesis may be breaking down and a downgrade to Underweight would be warranted.

CATALYSTS TO MONITOR: Q3 2026 earnings (expected October): Watch for commentary on Tomahawk ramp execution, GTF inspection cost trajectory, and 2027 guidance; defense budget negotiations and continuing resolution drama; geopolitical developments (Iran, Ukraine, Indo-Pacific) — tail risk for ceasefire-driven multiple compression; long-end Treasury yield trajectory — sustained move above current 19-year highs would pressure the 28.7x forward multiple.

The investment plan presents a balanced quality-vs-timing tension that argues for maintaining the existing position without adding. The structural thesis remains intact — Q2 2026 showed revenue of $24.71B (+14.5% YoY), operating income growth of 30.7% YoY running ahead of revenue (margin expansion), and EPS of $1.57 (+28.7% YoY), backed by a real $22.9B Tomahawk contracted backlog. However, the tactical setup argues against aggressive buying: RSI at 71.7 after a 17% rally in 5 weeks, MACD histogram turning negative at -0.40, price at 78% of Bollinger Band range, and a tepid 1% reaction to the major contract catalyst signals market skepticism. The 28.7x forward P/E is rich for a defense industrial historically trading at 15-20x, and quality concerns (NPM 8.3%, ROE 12.3%, $52.9B goodwill) are real. Selling a quality compounder on a technical wobble would be a mistake, but chasing at current levels offers poor risk/reward.

Stop loss: $199.50

Sizing: Maintain current weight; do not exceed benchmark exposure pending better entry. If underweight, accept the underweight and add on weakness rather than chasing to neutral at $225+.